Pandemic Influenza Articles & Analysis
11 news found
Influenza A virus is a genus of virus in the family Orthomyxoviridae and causes influenza in birds and some mammals. ...
These features, and the speed at which Lumen can advance from product concept to GMP-manufactured drug product, offers society a new rapid-response tool for countering future pandemics. The approach is directly translatable to other respiratory viral pathogens with pandemic potential, where interruption of disease transmission will aid in efforts to prevent ...
The funding is provided by BARDA to support the advanced research and development of medical countermeasures (MCM) for chemical, biological, radiological and nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases that threaten the U.S. civilian population. ...
This new study will build on Enesi’s successful Biomedical Advanced Research and Development Authority (BARDA) Drive Beyond the Needle collaboration earlier this year, under which the company successfully developed a number of solid-dose formulations of a recombinant H7N9 pandemic influenza vaccine. Under NIAID’s suite of preclinical services, ...
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. Enesi Pharma (“Enesi”), an innovative biotechnology company ...
About CSL CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent seasonal and pandemic influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. ...
In contrast, conventional endotracheal tubes allow pathogenic bacteria to grow on the tube surfaces within hours and form slime-like aggregations of millions of pathogenic cells as a biofilm. In the 1918 influenza pandemic, 95% of influenza patient deaths were caused by secondary bacterial infections. ...
“The year 2018 marks the 100- year anniversary of the Great Influenza Pandemic that killed at least 50 million persons worldwide in a span of 24 weeks. We do not know what might trigger a future deadly pandemic, but the situation with C. auris is worrisome. We are thankful to CDC for providing this valuable testing and we plan to work ...
“The preclinical results we have obtained make us confident in the ability of our IMX313P-based influenza vaccine candidate to improve the effectiveness of current seasonal influenza prevention,” said Alexandre Le Vert, Chief Executive Officer of Imaxio. ...
Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded a funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project: “leveraging On t-cell immune resPonse To Improve influenza VACcines”. The aim of the OPTIVAC project is to improve the ...
The widespread assumption that pandemic influenza is an exceptionally deadly form of seasonal, or nonpandemic, flu is hard to support, according to a new study in the May issue of the American Journal of Public Health. The study challenges common beliefs about the flu--in particular the Centers for Disease Control and Prevention (CDC) claim that 'the hallmark of ...